Exicure, Inc. (XCUR)
Last updated: 2026-10-28 11:13:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Exicure, Inc. (XCUR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.08, with a market capitalization of $7.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.94 to $9.48. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$7.14M | |
$1.09 | |
$576.00 | |
$0.94 | |
$1.07 | |
1.71K | |
46.20K | |
-- | |
$9.48 | |
$0.94 | |
-- | |
-- |
Exicure, Inc. (XCUR) Pre-Market Stock Price
Exicure, Inc. (XCUR) is trading at $1.08 in pre-market trading as of 2026-10-28 10:52:00, up 0.84% ($0.01) from the previous close of $1.07
Pre-market trading shows how investors are pricing XCUR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Exicure, Inc. (XCUR) 7-Day Stock Price Change
Over the past seven days, Exicure, Inc. (XCUR) moved from $1.03 to $1.08, representing a gain of 4.76% ($0.05).
The stock traded between $0.97 and $1.30 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 101.05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
XCUR 52-Week Price Position
Position in Range: 1.7%
XCUR is currently trading at $1.08, placing it 1.7% of the way from its 52-week low of $0.94 to its 52-week high of $9.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Exicure, Inc. (XCUR)?
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Exicure, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Exicure, Inc. (XCUR) Stock on MEXC
Eligible investors can buy real shares of Exicure, Inc. (XCUR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Exicure, Inc. (XCUR) stock price today?
2.Is XCUR stock going up or down today?
3.What is XCUR pre-market price?
4.What is XCUR after-hours price?
5.Is XCUR stock trading now?
6.Where does XCUR sit relative to its 52-week high and low?
7.What sector is Exicure, Inc. in?
8.What is Exicure, Inc.'s market capitalization and where is it listed?
9.How is XCUR valued in terms of P/E ratio and EPS?
10.Does Exicure, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
XCUR Stock Calculator
Estimate the value between XCUR shares and USD.
XCUR Shares to USD
1.00 XCUR shares = 1.079 USD
Calculations are estimates based on the latest available price and are for reference only.


